Skip to main content
Premium Trial:

Request an Annual Quote

GSK Expands Valentis Gene Expression License

NEW YORK, Dec. 17-GlaxoSmithKline has expanded its license to Valentis' gene expression technology, Valentis said today.

 

The two companies agreed in April 2001that the pharmaceutical company would have access to GeneSwitch, a technology that allows researchers to control activity of select genes in transgenic animals or cell cultures.

 

Under the current expanded agreement, GlaxoSmithKline will have  nonexclusive access to the technology for up to 10 years. Valentis will receive $1 million and continued rights to the clinical applications of the technology.

The Scan

UCLA Team Reports Cost-Effective Liquid Biopsy Approach for Cancer Detection

The researchers report in Nature Communications that their liquid biopsy approach has high specificity in detecting all- and early-stage cancers.

Machine Learning Improves Diagnostic Accuracy of Breast Cancer MRI, Study Shows

Combining machine learning with radiologists' interpretations further increased the diagnostic accuracy of MRIs for breast cancer, a Science Translational Medicine paper finds.

Genome Damage in Neurons Triggers Alzheimer's-Linked Inflammation

Neurons harboring increased DNA double-strand breaks activate microglia to lead to neuroinflammation like that seen in Alzheimer's disease, a new Science Advances study finds.

Long COVID-19 Susceptibility Clues Contained in Blood Plasma Proteome

A longitudinal study in eBioMedicine found weeks-long blood plasma proteome shifts after SARS-CoV-2 infection, along with proteomic signatures that appeared to coincide with long Covid risk.